Starting from June 2018, many important policies will officially come into effect. Noteworthy among these are the policies related to the fields of Healthcare - Pharmaceuticals, which are discussed in the article below.
Article table of contents
1. The Drug Name Must Not Be Advertised
According to the provisions of Circular 01/2018/TT-BYT which took effect from June 1, 2018, the trade name of the drug on the drug label must ensure:
- It is not advertised;- It does not mislead about the drug's ingredients or origin;- It does not mislead or overly describe the drug's effects, efficacy, indications, and other notable aspects.
2. List of Drugs Restricted for Retail Sale
To ensure safety and efficacy, and to avoid drug abuse leading to drug dependency in treatment, the Ministry of Health issued the List of Drugs Restricted for Retail Sale attached to Circular 07/2018/TT-BYT.
Based on the disease structure of the locality, the Department of Health will issue a document allowing the retail sale of certain drugs from this List.
See more specific regulations in Circular 07/2018/TT-BYT which details several provisions of the Pharmaceutical Law and Decree 54/2017/ND-CP detailing some provisions and measures for implementing the Pharmaceutical Law.
3. Change of Planning Time for the Demand for HIV Antiretroviral Drugs to March
Circular 08/2018/TT-BYT amends and supplements some provisions of Circular 28/2017/TT-BYT regarding the management of centrally procured HIV antiretroviral drugs using the health insurance fund and cost-sharing support for HIV patients with health insurance cards.
Before March 10, the healthcare facilities must send their drug use demand proposal to the provincial anti-HIV/AIDS specialized agency.
By April 1, the provincial anti-HIV/AIDS specialized agency must send the proposal to the Department of HIV/AIDS Prevention and Control. By April 30, the Department of HIV/AIDS Prevention and Control must send the proposal to the procurement unit.
4. Four Cases Where Drugs Must Be Tested by the Ministry of Health Before Circulation
Including:
- Vaccines, biological products containing antibodies;- Biological products derived from human blood and serum;- Imported drugs as stipulated in Article 70 of Decree 54/2017/ND-CP;- Drugs produced by foreign drug manufacturing facilities on the list of facilities with quality-violating drugs announced by the Ministry of Health.
The above content is based on Circular 11/2018/TT-BYT which takes effect from June 20, 2018, regulating the quality of drugs and drug materials.
